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Summary Weekly chemotherapy with cyclophosphamide 80mgm-2 day-' p.o. continuously, methotrexate
35 mg m2 week-' i.v., 5-fluorouracil 500 mg m2 weekl' i.v., vincristine 1.4 mg m -i.v. every two weeks and
prednisolone 20mg m2 day-' p.o. continuously (CMFVP) was prospectively studied in 45 previously un-
treated outpatients with advanced breast cancer to determine the feasibility of delivering a dose-intense
regimen. Of 40 evaluable patients, complete response (CR) occurred in one patient, partial response (PR) in 20
(CR + PR 53%), stable in eight, progression in 11 and five were unevaluable for response. The median
relapse-free survival for responders was 25 weeks and median survival for all patients was 31 weeks. The mean
dose intensity relative to the Cooper regimen fell from 1.02 to 0.6 within the first 4 weeks of treatment and the
median dose intensity achieved for all patients on study was only 0.52. Eighty-seven per cent of patients had
treatment delays with a mean of 3.9 delays per patient and 71% had dose reductions. Neutropenia was the
major toxicity with WHO grade 3 or 4 neutropenia (<1.0 x 10 1'-) in 62% of patients and three septic
deaths while neutropenic. Dose-intense weekly CMFVP in this schedule cannot be delivered to previously
untreated outpatients with advanced breast cancer.
Chemotherapy for advanced breast cancer using the com-
bination cyclophosphamide, methotrexate, 5-fluorouracil
+ prednisolone CMF(P) given in a conventional intermittent
schedule produces objective responses in approximately 50%
of patients, with a response duration of 9 months (Smalley et
al., 1983; Tormey et al., 1982). More recently attention has
been directed towards the dose and schedule of therapy as a
method of improving results with CMF in this disease.
The Cooper regimen, which included vincristine (CMFVP)
and used a weekly schedule, appeared to be well tolerated
with high responses in advanced disease and satisfactory
results as adjuvant chemotherapy (Cooper, 1969; Cooper et
al., 1979). Hryniuk and Bush (1984) have studied the dose
intensity of C, M and F in published data by converting each
dose of drug to mg m-2 week-1 and comparing it directly to
the Cooper regimen. They have concluded that many re-
ported CMF programmes deliver much less intense chemo-
therapy than Cooper described and that a dose-response
relationship may exist for C, M and F, especially if actual
doses delivered are studied. Hrynuik and Bush's review was
retrospective and not all published series of CMF(P) include
dose delivery data.
To determine the feasibility of delivering a dose-intense
regimen we studied a weekly CMFVP programme in pre-
viously untreated patients with advanced breast cancer. This
programme was designed to deliver a dose intensity of 1.02
relative to the Cooper regimen.
Materials and methods
Patients
Patients presenting to the Peter MacCallum Cancer Institute,
Melbourne, Australia, or Auckland Hospital, New Zealand,
with advanced metastatic breast cancer which was measur-
able or evaluable were eligible for this study. Eligible patients
had ECOG performance status (PS) 0-3, had not received
prior chemotherapy for advanced disease and a minimum of
6 months had elapsed since prior adjuvant chemotherapy.
Prior, but not concurrent, radiotherapy and endocrine ther-
apy were permitted.
Treatment plan
Patients received cyclophosphamide 80 mg m-2 day-' p.o.
continuously (560 mg m-2 week-'), methotrexate 35 mg m-2
i.v. weekly, 5-fluorouracil 500 mg m2 i.v. weekly, vincristine
1.4 mg m2 (maximum 2 mg) i.v. every 2 weeks and pred-
nisolone 20 mg m-2 day-' p.o. continuously (CMFVP). Pred-
nisolone was used in this dose so that it could be given in
equivalent dose intensity to the commonly used day 1 and
day 8 intermittent CMFP. One course was defined as four
successive weeks of treatment. Patients were seen and treated
weekly. Prochlorperazine 12.5 mg i.v. or 25 mg by supposi-
tory or metoclopramide 10-20 mg i.v. were routinely given
as anti-emetics.
Treatment was continued for at least 24 weeks unless
disease progression occurred. Standard WHO response cri-
teria were used (Miller et al., 1981). Relapse-free survival was
calculated for complete or partial responders only and was
measured from the first day of treatment. Time to disease
progression was calculated for all patients and measured
from the first day of therapy.
All toxicity was prospectively recorded weekly using WHO
toxicity criteria (Miller et al., 1981). To assess this prog-
ramme as an outpatient regimen, treatment was delayed if
neutrophils were < 1.5 x 109 1' (WHO grade 2) or platelets
<75 x 109 1'- (WHO grade 2) or if grade 2 or worse muco-
sitis or other toxicity occurred. Doses of C, M and F were
reduced by 25% if sepsis or bleeding occurred with WHO
grade 2 toxicity or for WHO grade 3 or 4 toxicity (neu-
trophils < 1.0 x 109 1'-). Vincristine was omitted for severe
neuropathy (WHO grade 3 or more).
Calculation ofdose intensity
Dose intensity was calculated for each patient by converting
the total dose of C, M, F and V into the dose received in
mg m-2 week-'. The dose intensities for each drug were then
expressed relative to the dose intensities of C, M, F or V in
the Cooper regimen (Cooper, 1969; Cooper et al., 1979)
(cyclophosphamide 560 mgm2 week-', methotrexate
28 mg m-2 week-', 5-fluorouracil 450 mg m-2 week-'), which
was taken as 1.0. The average dose intensity (DI) was then
calculated by averaging the DI of each drug and expressing it
as a three drug (CMF) or four drug (CMFV) DI. The DI of
the starting dose of the weekly programme outlined in the
treatment plan was 1.02 relative to Cooper. However, pred-
nisolone given in this programme is much more intense than
in the Cooper regimen but not included in the calculation of
dose intensity.
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Patients who failed to complete one course of treatment
(i.e. <4 weekly treatments) had a high calculated dose-in-
tensity but clearly inadequate therapy. These patients were
identified separately in our correlation of dose intensity with
response. Dose intensity was calculated for each patient
weekly. For each patient the profile of any change in dose
intensity was determined and the complete dose intensity
experience was called the cumulative dose intensity. The
average cumulative dose intensity for all patients was cal-
culated and graphed. The log rank test was used to compare
survival curves which were generated using the Kaplan-
Meier method (Peto et al., 1977).
Results
Patient characteristics
Forty-five patients were treated with weekly CMFVP. The
median age of patients was 55 years (range 31-79). On study
entry, eight had ECOG PS 0, 14 had PS 1, 13 had PS 2 and
10 had PS 3. Only five patients received prior adjuvant
chemotherapy and 37 had prior endocrine treatment. Sixteen
patients received no prior radiotherapy and 29 had limited
regional radiotherapy only. Only three patients had extensive
radiotherapy to >50% of bone marrow areas.
Tumour response
Five patients were inevaluable for response, two because of
early septic death; two because they received two or less
weekly doses and refused further treatment and one ceased
therapy after one dose following a perforated peptic ulcer.
All 45 patients are included on survival curves in calculations
of dose intensity. Of 40 patients evaluable for response, one
achieved a CR and 20 PR for an overall response (CR and
PR) of 53%, eight had stable disease and 11 progressed on
therapy. The median time to disease progression for all
patients was 19 weeks, relapse-free survival (for CR + PR)
was 25 weeks and median survival was 31 weeks.
Dose delivery
For all 45 patients, 651 weeks on study were documented
with 476 weekly treatments received. The first 27 patients
(60%) received full dose initially. The subsequent 18 patients
started 0.8 of the initial dose because of poor tolerance in the
first 27 patients. No patients started at doses <0.8 of pro-
tocol doses. Seventy-one per cent of all patients had dose
reductions of CMF on this program. A further 16% of
reductions were vincristine alone.
Nine per cent of patients had vincristine related grade 2 or
3 neurotoxicity requiring dose reduction or omission, 5%
had vincristine stopped with severe constipation and 2% had
vincristine stopped for mild neurotoxicity outside protocol
guidelines. Eighty-seven per cent of patients had one or more
treatment delays with a mean number of delays per patient of














before relapse or progression by the physician because of
toxicity and a further 16% stopped because of patient re-
fusal.
Toxicity
The major toxicity encountered was haematological with
WHO grade 3 or 4 neutropenia (<1.0 x i091'-) in 62 pa-
tients (Table I) and 38% of courses. Neutropenia was the
main cause of dose reduction and treatment delay. There
were three septic deaths associated with grade 4 neutropenia.
Two patients perforated duodenal ulcers, one while on ther-
apy and one patient within one month of completing ther-
apy. WHO grade 2-4 mucositis occurred in 28% of patients.
There were few gastrointestinal side-effects with WHO grade
2 or more nausea and vomiting in only 17% of patients.
Dose intensity
The median four drug DI achieved on this study was only
0.52 and three drug DI was 0.53 (Figure 2). The cumulative
mean four drug DI dropped from 1.02 at the start of therapy
to 0.6 after only four weekly treatments (Figure 3).
Correlation ofdose intensity and clinical outcome
The numbers compared are small and no correlation could
be detected between four drugs DI and clinical response
(Figure 4). Since the median four drug DI was 0.52, patients
were divided into two groups with DI <0.52 and >0.52.
These groups were well balanced for pre-treatment charac-
teristics such as age and performance status. There were no
differences detected in time to disease progression or relapse-
free survival for these two groups. The median survival of
patients receiving DI >0.52 was 36 weeks and 30 weeks for
DI <0.52 (P = 0.8). Similarly, there was no correlation de-
tected between any of these clinical outcomes and three drug
DI.
Table I Toxicity of patients receiving weekly CMFVP (n = 45)
WHO grade (%)
0 1 2 3 4
Haemoglobin 27 33 24 11 2
Neutrophils 11 18 7 38 24
Platelets 64 22 6 0 4
Mucositis 51 20 15 1 1 2
Nausea and vomiting 42 40 15 2 0
Alopecia 47 13 24 16 0
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Figure 4 Correlation of dose intensity and response.
Discussion
This weekly CMFVP programme produced objective res-
ponses in 53% of evaluable patients and 47% of all study
patients. The median duration of objective response (CR or
PR) was 25 weeks. These results are similar and not superior
to published data with CMF(VP) given on intermittent sche-
dules (Smalley et al., 1976, 1983; Tormey et al., 1982; Muss
et al., 1977). Cooper's results with weekly CMFVP are out-
standing, but the intensity of the dose actually delivered on
that programme has not been assessed (Cooper, 1969;
Cooper et al., 1979).
Patients entered on this study were not heavily pre-treated
and would not be expected to have compromised bone mar-
row function. Only five had received prior adjuvant chemo-
therapy and had not received any chemotherapy for at least 6
months. Only three patients had received extensive prior
radiotherapy while others received either no radiation or
limited regional therapy only. Only four patients had proven
or suspected bone marrow metastases. However, grade 3 or 4
neutropenia occurred in 62% of patients, with three septic
deaths associated with grade 4 neutropenia even with the
conservative policy of delaying therapy when neutrophils fell
below 1.5 x 109 1-' and of dose reductions for grade 3 or 4
cytopenia.
Neutropenia was the major cause of dose reduction in
71% of patients. It also caused treatment delays in 87%.
Most dose reductions or delays due to neutropenia occurred
in the first 4 weeks of treatment with the mean cumulative
dose intensity falling from 1.02 to 0.6 at four weeks (Figure
3). Thus, weekly treatments at this dose cannot be sustained
and this was not due to prolonged chemotherapy with an
increasingly compromised bone marrow. Following a delay,
we attempted to recommence the same dose ofchemotherapy
as suggested by a mean of four treatment delays per patient.
However, on average, only half of the intended dose intensity
could be finally delivered even in patients who had 0.8 of the
starting dose. Thus, it is unlikely that weekly CMFVP can be
applied intensively without a commitment to prolonged hos-
pitalisation in most patients.
The programme was otherwise well tolerated with little
gastrointestinal toxicity. In 16% of patients, vincristine had
to be withdrawn because of neurotoxicity. Weekly therapy
doubled the size of an already large outpatient clinic and
resulted in seven patients refusing further therapy.
Similar continuous but less intense regimens have been
randomly compared to intermittent CMFVP and achieved
improved responses but no differences in survival (Smalley et
al., 1976; Muss et al., 1977). Increased dose intensity of
doxorubicin has resulted in increased objective responses
(Jones et al., 1987). Hyrniuk and Bush (1984) in a retrospec-
tive analysis suggested that improvements in the treatment of
advanced breast cancer may result from delivery of more
dose intense therapy. Patients randomised to dose escalation
and protected environment using chemotherapy with 5-fluoro-
uracil, doxorubicin and cyclophosphamide (FAC) failed to
demonstrate an advantage for more intense therapy (Hor-
tobagyi et al., 1987). However, in that study a relatively
narrow dose intensity range was achieved
In this prospective study, no clear correlation or trend for
improved response, time to progression, relapse-free survival
or survival could be detected for patients with higher dose
intensity. However, the number of patients in whom we have
made clinical correlations with dose intensity are small and
the range of dose intensity is quite small so that firm con-
clusions regarding the value of increased dose intensity can-
not be made. A randomised study design comparing two
regimens with substantially different dose intensity is required
to resolve this issue.
High dose prednisolone, when added to standard intermit-
tent CMFP, significantly improved response duration and
survival in a randomised trial (Tormey et al., 1982). The
combination incorporating high dose prednisolone, CMFP,
has been widely used in Australia and was shown to be
equivalent to adriamycin and cyclophosphamide in pre-
viously untreated patients (Coates et al., 1987). In addition,
we planned this phase II study with the same dose intensity
of prednisolone so that it could be compared with standard
intermittent CMFP in subsequent studies. However, the
prednisolone may have contributed to the toxicity in two
patients who perforated duodenal ulcers.
We were unable to deliver dose-intense therapy to out-
patients with this weekly schedule. Other methods of dose
intensification such as high dose, intermittent schedules, with
bone marrow rescue or recombinant colony stimulating fac-
tors may be more productive (Eder et al., 1986).
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